Results 71 to 80 of about 5,685 (219)
Journal of Pharmacy Practice and Research, Volume 55, Issue 6, Page 447-457, December 2025.Abstract Aim Guidelines recommend initial anticoagulant management of acute coronary syndrome (ACS) with low molecular weight heparin (LMWH) such as enoxaparin or unfractionated heparin (UFH). Systematic reviews evaluate early trials in the context of multiple other medications or during percutaneous coronary intervention (PCI) only.
Krishna Doshi +2 more
wiley +1 more source
Рациональная фармакотерапия в кардиологии, 2019 Background. Eptifibatide achieves high local concentration via direct intracoronary (I/V) injection as it promotes clot disaggregation, but it remains unclear if it is of superior benefit than the routine intravenous (I/V) administration. Aim.
Mohamed Hassan Nab +4 more
doaj +1 more source
American Journal of Cardiology, 2020 The glycoprotein IIb/IIIa inhibitor eptifibatide, administered as bolus followed by infusion, is an adjunctive antithrombotic treatment during primary percutaneous coronary intervention (PCI) in selected patients with ST-segment elevation myocardial ...
F. Fischer +7 more
semanticscholar +1 more source
The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors
British Journal of Pharmacology, Volume 182, Issue S1, Page S259-S306, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +31 more
wiley +1 more source
, 2001 OBJECTIVESWe sought to investigate whether abciximab, tirofiban and eptifibatide achieve comparable antiplatelet effects with coronary stenting.BACKGROUNDThe glycoprotein (GP) IIb/IIIa antagonists abciximab, tirofiban and eptifibatide differ in chemical ...
Pogatsa-Murray, Gisela +9 more
core +1 more source
Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper
Allergy, Volume 80, Issue 11, Page 2973-2987, November 2025.ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Gabriele Cortellini +10 more
wiley +1 more source
, 2013 A. Eptifibatide treated mice had lower sepsis scores than vehicle treated mice at time points following drug administration. For example, at the 20 hour injection, the mean±SEM vehicle treated score was 8.4±0.3 while the eptifibatide treated score was 7 ...
Angela S. Benton (314055) +7 more
core +1 more source
Iranian Journal of Biotechnology, 2019 Background Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes in order to decreasing their side effects and improving their half ...
Hassan Bardania +6 more
semanticscholar +1 more source
Biomimetic Cell Membrane‐Coated Scaffolds for Enhanced Tissue Regeneration
Advanced Materials, Volume 37, Issue 40, October 9, 2025.This review examines the development and use of cell membrane‐coated scaffolds in tissue engineering. Bioinspired phospholipid and glycocalyx coatings enhance anti‐fouling, anti‐thrombogenic, and selective molecular recognition properties. Native cell membrane coatings further support cell‐specific interactions, immune modulation, and reduced bacterial
Carmen Alvarez‐Lorenzo +5 more
wiley +1 more source
Eptifibatide-induced thrombocytopenia leading to acute stent thrombosis
, 2016 A 71-year old female patient with inferior ST- elevation myocardial infarction underwent primary percu- taneous coronary intervention (PCI) within 3 h of symptom onset. She was preloaded with 300 mg aspirin and 600 mg clopidogrel before PCI.
Faluközy, József +6 more
core +1 more source